drugset / Trial / NCT05866679

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

NCT05866679

Phase 1 Suspended 30 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelDiagnostic

Summary

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.

Timeline

Start
2024-04-12
Primary completion
2026-08-31
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyperpolarized 13C-Pyruvate Diagnostic / imaging agent Oral

Indications